Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 23, 2021 16:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Present at the Ophthalmology Futures European 2021 Virtual Retina Forum

ALPHARETTA, Ga., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
August 10, 2021 16:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Second Quarter 2021 Financial Results and Provides Corporate Update

- Enrollment Underway in Cohort 2 of OASIS Wet AMD Phase 1/2a Trial with Data Expected by the End of 2021 – - Upcoming FDA PDUFA Action Date in October 2021 for XIPERE™ (triamcinolone acetonide...
August 04, 2021 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in August 2021

ALPHARETTA, Ga., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
July 27, 2021 16:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Tuesday, August 10, 2021

ALPHARETTA, Ga., July 27, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
June 15, 2021 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

- CLS-AX 0.03 mg dose delivered via suprachoroidal injection was well-tolerated with no treatment related adverse events - - Initiating Cohort 2 patient screening for 0.1 mg dose in June 2021 - ...
June 09, 2021 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021

ALPHARETTA, Ga., June 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
May 17, 2021 16:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update

- Recent New Drug Application Resubmission for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) - - Cohort 1 Data in OASIS Wet AMD Phase 1/2a Trial Expected in...
May 10, 2021 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Multiple Poster Presentations at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting

ALPHARETTA, Ga., May 10, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
May 04, 2021 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021

ALPHARETTA, Ga., May 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
May 03, 2021 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis

ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...